ClinicalTrials.gg
CompletedNCT03482635Updated Oct 16, 2025Results posted

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

A Phase 2/3 interventional study of Spesolimab and Placebo in Colitis, Ulcerative, sponsored by Boehringer Ingelheim. Completed at 54 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
233rd of 499
98 · median 76
Started
2018
with 33 others
Phase 2/3
16 of 615
1 open now
Registered
302nd of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 233rd largest by enrollment of the 499 interventional ones that give a count, is one of 34 that started in 2018, is one of 16 in phase 2/3, and was the 302nd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are

  • to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)
  • to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)
  • To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.
03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 75 years, at date of signing , males or females
  • Diagnosis of ulcerative colitis ≥ 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report
  • Moderate to severe activity (total MCS 6 to 12 with a RBS ≥ 1 AND an SFS ≥ 1 AND mESS ≥ 2 within 7-28 days prior to first dose)
  • Endoscopic activity extending proximal to the rectum (≥ 15 cm from anal verge)
  • Well-documented demonstration of inadequate response or loss of response or have had unacceptable side effects with approved doses of TNFɑ antagonists (infliximab, adalimumab, golimumab) and/or vedolizumab in the past (screening of both TNFɑ antagonists-AND-Vedolizumab failure patients will be capped once 48 randomized patients in Part 1 and 117 randomized patients in Part 2 meet this criterion; patients who have already been screened at the time of the cap will continue to be randomized into the study)
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Evidence of abdominal abscess at screening
  • Evidence of fulminant colitis or toxic megacolon at screening
  • Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
  • Further exclusion criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Group 1- Placebo Group

    Drug: Placebo

  • Experimental
    Group 2- Small Dose Group

    Drug: Spesolimab

  • Experimental
    Group 3- Medium Dose Group

    Drug: Spesolimab

  • Experimental
    Group 4 - High Dose Group

    Drug: Spesolimab

Interventions

  • Solution for infusion

  • DrugPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With Clinical Remission at Week 12

    Proportion of patients with clinical remission (defined as modified Mayo Clinical Score (MCS) ≤ 2, with Stool Frequency Score (SFS) = 0 or 1 \[if drop ≥1 from baseline\] and Rectal Bleeding Score (RBS) = 0 and modified Endoscopic Subscore (mESS) ≤ 1) at week 12. Proportion of patients was calculated as n/N, with n=number of patients with clinical remission at week 12 and N=number analyzed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.

    Time frame: At week 12.

Secondary outcomes

  1. Proportion of Patients With Clinical Response at Week 12

    Proportion of patients with clinical response (defined as Rectal Bleeding Score (RBS) ≤ 1 or decrease by ≥1 from baseline; and total Mayo Clinical Score (MCS) decrease by ≥ 3 and 30% from baseline) at week 12. Proportion of patients is calculated as n/N, with n=number of patients with clinical response at week 12 and N=number of patients analyzed. 95% Confidence Intervals (CI) are calculated using the method of Wilson.

    Time frame: At week 12.

  2. Proportion of Patients With Endoscopic Improvement at Week 12

    Proportion of patients with endoscopic improvement at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1) Proportion of patients was calculated as n/N, with n=number of patients with Endoscopic Improvment at Week 12 and N=number analysed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.

    Time frame: At week 12.

  3. Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12

    Proportion of patients with combined endoscopic improvement and histologic remission at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1 and Robarts Histology Index ≤ 6). Proportion of patients was calculated as n/N, with n= number of patients with Endoscopic Improvement and histologic remission at week 12 and N=number of patients analysed.

    Time frame: At week 12.

  4. Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12

    Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline at Week 12. The IBDQ is a 32-item self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The response options describe the magnitude or frequency of impairment from 1 (most severe) to 7 (no impairment). The items are summed up, resulting in a sum score ranging from 32 to 224 points, with higher scores indicating better outcomes. A score change of 16 is reported to reflect the minimal clinically important difference (MCID). Mean is adjusted mean.

    Time frame: At baseline and at week 12.

07

Results

Posted Jun 11, 2021
Limitations and caveats
Due to recruitment issues during phase II, the trial was prematurely ended according to a protocol defined option. Phase III was not conducted. The trial was completed as defined in the protocol.

Participant flow

Phase II/III randomized, placebo-controlled, double-blind trial to assess the safety and efficacy of spesolimab induction therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy. Phase III was not conducted, due to recruitment issues in Phase II.

Participant flow — Overall Study
MilestonePlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Started23242328
Treated23242327
Completed18212220
Not completed5318
Withdrew: Lack of efficacy0013
Withdrew: Adverse event2203
Withdrew: Withdrawal by subject2101
Withdrew: Withdrawn by principle investigator1000
Withdrew: Not treated0001

Outcome measures

PrimaryProportion of Patients With Clinical Remission at Week 12

Proportion of patients with clinical remission (defined as modified Mayo Clinical Score (MCS) ≤ 2, with Stool Frequency Score (SFS) = 0 or 1 \[if drop ≥1 from baseline\] and Rectal Bleeding Score (RBS) = 0 and modified Endoscopic Subscore (mESS) ≤ 1) at week 12. Proportion of patients was calculated as n/N, with n=number of patients with clinical remission at week 12 and N=number analyzed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.

Time frame:
At week 12.
Reported as:
Number · Proportion of Participants
Proportion of Patients With Clinical Remission at Week 12
Proportion of ParticipantsPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Proportion of Patients With Clinical Remission at Week 120.00 (0.000 to 0.143)0.042 (0.007 to 0.202)0.087 (0.024 to 0.268)0.071 (0.020 to 0.226)
Statistical analysis
  • Placebo vs 300 mg Spesolimab (BI 655130) SD · Risk difference (rd): 0.042 · 95% CI -0.105 to 0.202Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 450 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.087 · 95% CI -0.069 to 0.268Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 1200 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.071 · 95% CI -0.081 to 0.226Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
SecondaryProportion of Patients With Clinical Response at Week 12

Proportion of patients with clinical response (defined as Rectal Bleeding Score (RBS) ≤ 1 or decrease by ≥1 from baseline; and total Mayo Clinical Score (MCS) decrease by ≥ 3 and 30% from baseline) at week 12. Proportion of patients is calculated as n/N, with n=number of patients with clinical response at week 12 and N=number of patients analyzed. 95% Confidence Intervals (CI) are calculated using the method of Wilson.

Time frame:
At week 12.
Reported as:
Number · Proportion of participants
Proportion of Patients With Clinical Response at Week 12
Proportion of participantsPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Proportion of Patients With Clinical Response at Week 120.217 (0.097 to 0.419)0.167 (0.067 to 0.359)0.261 (0.125 to 0.465)0.250 (0.127 to 0.434)
Statistical analysis
  • Placebo vs 300 mg Spesolimab (BI 655130) SD · Risk difference (rd): -0.051 · 95% CI -0.276 to 0.176Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 450 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.043 · 95% CI -0.199 to 0.280Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 1200 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.033 · 95% CI -0.204 to 0.252Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
SecondaryProportion of Patients With Endoscopic Improvement at Week 12

Proportion of patients with endoscopic improvement at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1) Proportion of patients was calculated as n/N, with n=number of patients with Endoscopic Improvment at Week 12 and N=number analysed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.

Time frame:
At week 12.
Reported as:
Number · Proportion of participants
Proportion of Patients With Endoscopic Improvement at Week 12
Proportion of participantsPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Proportion of Patients With Endoscopic Improvement at Week 120.000 (0.000 to 0.143)0.083 (0.023 to 0.258)0.087 (0.024 to 0.268)0.071 (0.020 to 0.226)
Statistical analysis
  • Placebo vs 300 mg Spesolimab (BI 655130) SD · Risk difference (rd): 0.083 · 95% CI -0.072 to 0.258Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 450 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.087 · 95% CI -0.069 to 0.268Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
  • Placebo vs 1200 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.071 · 95% CI -0.081 to 0.226Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\]. 95% CI for risk difference were calculated using the method of Newcombe.
SecondaryProportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12

Proportion of patients with combined endoscopic improvement and histologic remission at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1 and Robarts Histology Index ≤ 6). Proportion of patients was calculated as n/N, with n= number of patients with Endoscopic Improvement and histologic remission at week 12 and N=number of patients analysed.

Time frame:
At week 12.
Reported as:
Number · Proportion of participants
Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12
Proportion of participantsPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 120.00 (0.000 to 0.143)0.083 (0.023 to 0.258)0.043 (0.008 to 0.210)0.036 (0.006 to 0.177)
Statistical analysis
  • Placebo vs 300 mg Spesolimab (BI 655130) SD · Risk difference (rd): 0.083 · 95% CI -0.072 to 0.258Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\].
  • Placebo vs 450 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.043 · 95% CI -0.104 to 0.210Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\].
  • Placebo vs 1200 mg Spesolimab (BI 655130) q4w · Risk difference (rd): 0.036 · 95% CI -0.110 to 0.177Unadjusted absolute risk difference to placebo, \[Treatment - Placebo\].
SecondaryChange in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12

Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline at Week 12. The IBDQ is a 32-item self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The response options describe the magnitude or frequency of impairment from 1 (most severe) to 7 (no impairment). The items are summed up, resulting in a sum score ranging from 32 to 224 points, with higher scores indicating better outcomes. A score change of 16 is reported to reflect the minimal clinically important difference (MCID). Mean is adjusted mean.

Time frame:
At baseline and at week 12.
Reported as:
Mean · Score on a scale
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12
Score on a scalePlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 1219.8 (4.7 to 35.0)19.5 (4.6 to 34.5)21.2 (6.6 to 35.9)20.8 (6.3 to 35.4)
Statistical analysis
  • Placebo vs 300 mg Spesolimab (BI 655130) SD · Mixed Models Analysis · p = 0.9776 · Difference of adjusted means: -0.3 · 95% CI -21.6 to 21.0
  • Placebo vs 450 mg Spesolimab (BI 655130) q4w · Mixed Models Analysis · p = 0.8940 · Difference of adjusted means: 1.4 · 95% CI -19.6 to 22.4
  • Placebo vs 1200 mg Spesolimab (BI 655130) q4w · Mixed Models Analysis · p = 0.9241 · Difference of adjusted means: 1.0 · 95% CI -20.0 to 22.1

Adverse events

Collected over From screening until end of study, up to 29 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/23 (0%)4/23 (17.4%)5/23 (21.7%)
300 mg Spesolimab (BI 655130) SD0/24 (0%)3/24 (12.5%)7/24 (29.2%)
450 mg Spesolimab (BI 655130) q4w0/23 (0%)2/23 (8.7%)7/23 (30.4%)
1200 mg Spesolimab (BI 655130) q4w0/27 (0%)3/27 (11.1%)17/27 (63%)
Most frequent serious events
Most frequent serious events
EventPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Colitis ulcerativeGastrointestinal disorders1/232/241/232/27
AnaemiaBlood and lymphatic system disorders1/230/240/231/27
Iron deficiency anaemiaBlood and lymphatic system disorders0/230/241/230/27
Clostridium difficile colitisInfections and infestations1/230/240/230/27
Femur fractureInjury, poisoning and procedural complications1/230/240/230/27
Infusion related reactionInjury, poisoning and procedural complications1/231/240/230/27
OsteonecrosisMusculoskeletal and connective tissue disorders1/230/240/230/27
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4w
Colitis ulcerativeGastrointestinal disorders0/232/241/236/27
AnaemiaBlood and lymphatic system disorders5/231/240/230/27
Feeling hotGeneral disorders0/230/243/230/27
HeadacheNervous system disorders0/230/241/233/27
NasopharyngitisInfections and infestations0/232/242/231/27
ErythemaSkin and subcutaneous tissue disorders0/230/242/230/27
RashSkin and subcutaneous tissue disorders0/231/242/232/27
SyncopeNervous system disorders0/232/240/230/27
Abdominal pain upperGastrointestinal disorders0/230/240/232/27
ConstipationGastrointestinal disorders0/230/240/232/27

Baseline characteristics

Randomised Set: The RS included all randomised patients. Treatment assignment was as randomised. It was the main analysis set for presentation of efficacy on binary endpoints.

Age, Continuous
Age, Continuous(Years)Placebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4wTotal
Mean42.2 ± 14.141.4 ± 14.642.3 ± 15.343.9 ± 14.942.5 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4wTotal
Female11710836
Male1217132062
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4wTotal
Hispanic or Latino00011
Not Hispanic or Latino2324232797
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo300 mg Spesolimab (BI 655130) SD450 mg Spesolimab (BI 655130) q4w1200 mg Spesolimab (BI 655130) q4wTotal
American Indian or Alaska Native00011
Asian414514
Native Hawaiian or Other Pacific Islander00000
Black or African American10113
White1823182180
More than one race00000
Unknown or Not Reported00000
08

Study locations

54 sites
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • University of Miami
    Miami, Florida 33136, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Columbia University Medical Center-New York Presbyterian Hospital
    New York, New York 10032, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Digestive Disease Specialists Inc
    Oklahoma City, Oklahoma 73112, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - Southlake
    Southlake, Texas 76092, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern
    Linz, A-4010, Austria
  • AKH - Medical University of Vienna
    Vienna, 1090, Austria
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • University of Manitoba - Health Sciences Centre
    Winnipeg, Manitoba R3A 1R9, Canada
  • Victoria Hospital (LHSC)
    London, Ontario N6A 5W9, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Universitätsklinikum Aachen, AöR
    Aachen, 52074, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen AöR
    Essen, 45147, Germany
  • Klinikum Esslingen GmbH
    Esslingen am Neckar, 73730, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24105, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Azienda Ospedaliera Universitaria di Padova
    Padova, 35128, Italy
  • Istituto Clinico Humanitas
    Rozzano (MI), 20089, Italy
  • Toho University Sakura Medical Center
    Chiba, Sakura, 285-8741, Japan
  • Sapporo Tokushukai Hospital
    Hokkaido, Sapporo, 004-0041, Japan
  • Sapporo Higashi Tokushukai Hospital
    Hokkaido, Sapporo, 065-0033, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, Nishinomiya, 663-8501, Japan
  • Sameshima Hospital
    Kagoshima, Kagoshima, 892-0846, Japan
  • Ofuna Chuo Hospital
    Kanagawa, Kamakura, 247-0056, Japan
  • Tokyo Medical and Dental University
    Tokyo, Bunkyo-ku, 113-8519, Japan
  • Kitasato Institute Hospital
    Tokyo, Minato-ku, 108-8642, Japan
  • Tokyo Yamate Medical Center
    Tokyo, Shinjuku, 169-0073, Japan
  • Health Center of Mother, Child and Youth Sp.z o.o.
    Warsaw, 00-632, Poland
  • Central Clinical Hospital MSWiA, Internal Diseases, Warsaw
    Warsaw, 02-507, Poland
  • FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien.
    Irkutsk, 664003, Russia
  • Kirov State Med.Univ. of MoH RF
    Kirov, 610027, Russia
  • Federal State Budgetary Institution " State Scientific Center of Coloproctology" MOH Russia
    Moscow, 123423, Russia
  • Reg. Clin. Scientific Research Institute na Vladimiskiy
    Moscow, 129110, Russia
  • The limited liability company "Clinic USI 4D"
    Pyatigorsk, 357502, Russia
  • FSBMEI HPE "Military Medical Academy n.a. S.M. Kirov"
    Saint Petersburg, 194044, Russia
  • Inje University Haeundae Paik Hospital
    Busan, 48108, South Korea
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Hospital Virgen del Rocío
    Seville, 41013, Spain
  • Hospital Politècnic La Fe
    Valencia, 46026, Spain
  • Barnsley Hospital
    Barnsley, S75 2EP, United Kingdom
  • Doncaster Royal Infirmary
    Doncaster, DN2 5LT, United Kingdom
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
  • Whiston Hospital
    Prescot, L35 5DR, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in May 2020, 25 months.

Results were first posted in Jun 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2018
First posted
Mar 29, 2018
StartActual
Mar 27, 2018
Primary completionActual
May 18, 2020
CompletionActual
May 18, 2020
Results first posted
Jun 11, 2021
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03482635
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 27, 2018
Primary completion
May 18, 2020
Completion
May 18, 2020
Results posted
Jun 11, 2021
Last update
Oct 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spesolimab

Start the discussion